COMBACTE-CDI Understanding the Burden of C. Difficile Infection (COMBACTE-CDI)
Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections (COMBACTE-CDI, Understanding the Burden of Disease
Sponsor: AstraZeneca
Listed as NCT03503474, this observational or N/A phase trial focuses on Clostridium Difficile Infection and remains completed. Sponsored by AstraZeneca, it has been updated 10 times since 2018, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Feb 2025 — Present [monthly]
Completed
-
Sep 2024 — Feb 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 5 earlier versions
-
Mar 2022 — Dec 2022 [monthly]
Completed
Status: Unknown Status → Completed
-
Dec 2021 — Mar 2022 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
Status: Not Yet Recruiting → Unknown Status
-
May 2018 — Nov 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- BioMérieux
- Da Volterra
- GlaxoSmithKline
- Innovative Medicines Initiative
- Leiden University Medical Center
- National Institute for Infectious Diseases 'Lazzaro Sapllanzani', Italy
- National laboratory for Health, Environment and Food, Slovenia
- Pfizer
- Sanofi Pasteur, a Sanofi Company
- UMC Utrecht
- Universiteit Antwerpen
- University of Leeds
- Universität Tübingen
- Universitätsklinikum Köln
For direct contact, visit the study record on ClinicalTrials.gov .